Catalyst

Slingshot members are tracking this event:

Cardiome Announces Proposed Public Offering of Common Shares

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CRME

100%

Additional Information

Additional Relevant Details Cardiome has commenced a proposed underwritten public offering (the "Offering") of shares of its common stock. In addition, Cardiome expects to grant the underwriters of the Offering a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the Offering on the same terms and conditions.


Cardiome intends to use the net proceeds from the Offering for the in-licensing of dalbavancin, including for the upfront licensing fee pursuant to the exclusive license agreement with Allergan plc, and for milestone payments related to pricing reimbursements and launches. Any remaining net proceeds from the Offering will be used for general corporate purposes.
http://www.cardiome....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Public Offering Of Common Stock, Dalbavancin